Table A2.
IP/IV Regimens by Institution From 2003 to 2012 (cohort 1)
| Regimen | Overall % (N = 287) | Patients Receiving IP/IV by Institution (%)* |
|||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | ||
| IP/IV with GOG-172, %† | 29 | 48 | 49 | 0 | 63 | 13 | 0 |
| IP/IV on clinical trial, % | 28 | 19 | 27 | 87 | 30 | 0 | 30 |
| Modified IP/IV regimen, %‡ | 43 | 32 | 24 | 13 | 7 | 87 | 70 |
| IV drug substitution | 23 | 3 | 0 | 0 | 4 | 17 | 66 |
| IP drug substitution | 1 | 10 | 0 | 0 | 0 | 0 | 0 |
| IP dose reduction | 16 | 16 | 24 | 13 | 0 | 70 | 0 |
| Other | 2 | 3 | 0 | 0 | 4 | 0 | 4 |
Abbreviations: GOG, Gynecologic Oncology Group; IP, intraperitoneal; IV, intravenous.
*
Absolute numbers are suppressed to protect the identity of individual institutions.
†
GOG-172 regimen is IV paclitaxel, 135 mg/m2, on day 1, IP cisplatin, 100 mg/m2, on day 2, and IP paclitaxel, 60 mg/m2, on day 8.
‡
Examples include IV drug substitution (eg, docetaxel instead of paclitaxel), IP dose reduction (eg, cisplatin, 75 instead of 100 mg/m2), IP drug substitution (eg, carboplatin for cisplatin), or combined adjustments (eg, IV docetaxel and IP carboplatin).